Data Methods
Learn more about the data that informs America's HIV Epidemic Analysis Dashboard (AHEAD) on this webpage.
Learn more about the data that informs America's HIV Epidemic Analysis Dashboard (AHEAD) on this webpage.
This Funding Opportunity Announcement (FOA) invites submission of investigator-initiated Program Project (P01) applications.
This Funding Opportunity Announcement (FOA) supports research from creative early stage investigators who propose highly innovative, pioneering studies with potential to open new areas of HIV/AIDS related to coinfections, comorbidities, and complications. Projects should reflect new and novel scientific directions that are distinct from concepts and approaches being pursued in the investigators research program or elsewhere. Projects must be consistent the scientific priorities outlined by the NIH Office of AIDS Research (OAR).
This Funding Opportunity Announcement (FOA) is a part of NIDAs Racial Equity Initiative (REI), a multi-year, multi-pronged effort to eliminate racial inequities in NIDAs workplace, scientific workforce, and research portfolio. The purpose of this initiative is to support pilot or feasibility research on structural factors, organizational practices, policies, and other social, cultural, and contextual influences that lead to inequities at the intersection of HIV and substance use among underserved racial/ethnic populations affected by persistent HIV disparities.
The objective of this Funding Opportunity Announcement (FOA) is to support the continued development of new and innovative on-demand, event-driven, and long-acting (systemic and non-systemic) multipurpose prevention technologies (MPTs). It supports development of MPTs that prevent HIV infection and pregnancy (hormonal and non-hormonal methods); sexually transmitted infections (STI) and pregnancy; or multiple non-HIV STI or HIV/STI MPTs in cis and trans males and females of all ages.
This success story provides information on an analysis tool used to help public health labs identify genes involved in drug-resistant gonorrhea.
This report summarizes provisional TB surveillance data reported to CDC’s National Tuberculosis Surveillance System in 2012. A total of 9,951 new TB cases were reported for an incidence of 3.2 cases per 100,000 population, which is a decrease of 6.1 percent from the incidence in 2011. TB incidence rate among foreign-born persons in the United States was 11.5 times as high as in US-born persons. Also, racial/ethnic disparities in TB incidence persist with TB rates among non-Hispanic Asians, Hispanics, and non-Hispanic blacks were 25.0, 6.6, and 7.3 times as high respectively.
This report provides provisional CDC guidelines for FDA-approved and unapproved, or off-label, uses of bedaquiline in certain populations who were not included in the clinical trials for the drug. These guidelines are intended for health-care professionals who might use bedaquiline for the treatment of MDR TB for indicated and off-label uses. Aspects of these guidelines are not identical to current FDA-approved labeling for bedaquiline.